Opis przypadku pacjenta z perforacją podniebienia twardego i oskrzeli w przebiegu ziarniniakowatości z zapaleniem naczyń (ziarniniaka Wegenera) leczonego rituximabem
Introduction
Granulomatosis with polyangiitis (GPA), previously known as Wegener's granulomatosis, is a systemic vasculitis affecting small and medium-size blood vessels involving upper airways, lungs, and kidneys [1] [2] [3] [4] . The majority of patients with GPA show the presence of anti-neutrophil cytoplasmic antibodies (ANCA) directed against proteinase 3 (anti-PR3) [3, 5] . If GPA is left untreated, it usually leads to rapid progression and death [5] . Mean survival of untreated patients is 5 months, with more than 90% of patients dying within 2 years of diagnosis [3, 6] . Conventional treatment comprises cyclophosphamide combined with glucocorticoids, which substantially improves GPA prognosis [3, 7, 8] . However, some patients with GPA are refractory to this treatment [8] .
Here we present a case of a patient suffering from GPA refractory to conventional treatment with both hard palate and bronchial perforations, who went into remission after rituximab therapy.
Case
We describe a case of a 57-year-old woman with a seven-month history of nasal discharge, chest pain, polyneuropathy, arthralgia, hearing loss, and CT-confirmed pansinusitis. She had not taken cocaine in the past, which is one of the most common causes of bone and cartilage destruction of the nose. Granulomatosis with polyangiitis (GPA) was diagnosed based on clinical manifestations and the presence of ANCA (with a serum titre 1:320, confirmed as anti-PR3 194RU/ /mL by ELISA). In addition, bronchial mucosa biopsy showed inflammatory granuloma with necrosis. She was then aggressively treated with monthly i.v. doses (15 mg/kg of body weight) of cyclophosphamide and with i.v. methylprednisolone (1 mg/kg), followed by oral prednisone with a gradual taper from 40 mg per day, with initial clinical improvement. In the seventh month of treatment (a total of 6.3 g of cyclophosphamide received) progression of the disease was observed, manifesting as reappearance of chest pain and cough, accompanied by several perforations on the hard palate (Fig. 1A) . Bronchoscopy revealed additional perforations of the trachea at the level of the carina ( Fig. 2A) and bilaterally in the lobar bronchi. Treatment was changed to pulses of methylprednisolone (500 mg for 3 days, followed by 1 mg/kg/day) and three weekly doses of rituximab (375 mg/m 2 ) resulting in blood B-cell depletion and disappearance of anti-PR3 antibodies. A few weeks later palatal holes diminished in size (Fig. 1B) and all bronchial perforations disappeared, covered by fibrous tissue (Fig. 2B ). In the fourth month after rituximab administration, scarring and substantial obstruction of the right main bronchus developed with atelectasis of the upper and middle lobes of the right lung. The patient was transferred to the thoracic surgery department, where the right main bronchus was re-opened using bronchoscopy. The procedure was complicated by bilateral pneumothorax. On the seventh day after the procedure fatal pulmonary bleeding developed and the patient died.
Discussion
GPA is a rare disease with an annual incidence ranging from 0.5 to 10 cases per million people [6, 9] . This form of vasculitis usually manifests in The course of GPA is variable -from slow to rapid progression leading to life-threatening multiorgan failure, which invariably leads to death [15] . Conventional induction treatment comprises cyclophosphamide combined with glucocorticoids [7] . Unresponsive cases have recently been treated by rituximab [15] . Rituximab, an anti--CD20 monoclonal antibody developed to treat B-cell malignancies, has also been used recently in the treatment of several autoimmune diseases [15] [16] [17] . It leads to a rapid depletion of CD20 cells from the circulating blood paralleled by a significant decrease in disease activity observed in the first 6 months in up to 88% of patients [3, 7, [16] [17] [18] [19] [20] [21] . We used rituximab in our patient because of GPA progression despite conventional cyclophosphamide treatment. It manifested with three large hard palate perforations and multiple perforations in the trachea and bronchi. Only a few cases of GPA with palate perforations were reported, and most of these patients were treated with glucocorticoids and cyclophosphamide with temporary benefits [22, 23] . To the best of our knowledge, nobody has previously described GPA with palate perforations associated with tracheal and bronchial perforations, which appeared during standard cyclophosphamide i.v. therapy. Beneficial effects of rituximab in our patient (partial or complete healing) were associated with the disappearance of ANCA from peripheral blood. Preferred regimen of rituximab administration in GPA includes four (500 mg) or two (1000 mg) weekly doses, leading to disease remission in the majority of patients [17] . Maximal effectiveness of rituximab is often observed when anti-CD20 antibody is administered in combination with glucocorticoids [15] . Rituximab B-cells return to peripheral blood 9-12 months after infusion [18] .
For this reason, in GPA some physicians suggest additional doses of rituximab every six months [17] . Rituximab is very well tolerated; major infections during the B-cell depletion treatment are uncommon [16] . General experience in treating of GPA patients with respiratory tract perforations is very limited [22, 23] . However, it seems that rituximab might be an option in such patients, especially if they are unresponsive to cyclophosphamide.
